ClinicalTrials.gg

Spinal Cord Injuries clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 2,028 studies for Spinal Cord Injuries across more than 10 countries. 540 are recruiting or about to start. 1,625 of them are mainly about Spinal Cord Injuries (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 2 narrower conditions too, such as Spinal Cord Compression: 2,079 studies, 556 open.

ClinicalTrials.gov finds 2,267 studies for Spinal Cord Injuries. How that becomes 2,028 here

This page counts the studies the registry files under Spinal Cord Injuries, and those it files under no condition that list Spinal Cord Injuriesthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 2,267Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −45Filed under a narrower condition, counted on its own pageSpinal Cord Compression 40 · Autonomic Dysreflexia 5
  3. −47List Spinal Cord Injuries as a condition, but the registry did not file them under itMost often written as “Cervical Spinal Cord Injury” (17), “Incomplete Spinal Cord Injury” (10), and “Spinal Cord Injury Cervical” (6). The registry filed them under other conditions only, most often Quadriplegia (17) and Stroke (9).
  4. −147Match it another way77 name it in the title, 11 in a keyword, and 59 by a synonym or other text the search reads.
  5. 2,028The count on this page78 of them list Spinal Cord Injuries in their own words; the registry filed them under no condition.

Status

Completed
1,021
Recruiting
376
Status unknown
202
Not yet recruiting
127
Terminated
109
Active, not recruiting
91

Phase

Phase 2
229
Phase 1
152
Phase 3
69
Phase 4
54
Early Phase 1
30

Where

United States
968
Canada
203
Switzerland
111
China
80
United Kingdom
65
France
64

Who develops what

Add Spinal Cord Injuries to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 6 programs from 5 companies, 6 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 6 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jun 2027 est.EG110A · Cyllene Therapeutics · Phase 2 main aimNCT06596291 Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization — primary endpoint: Incidence of treatment-emergent adverse events (TEAEs) · 16 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Spinal Cord Injuries studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Androgens 2 open · Cholinesterase inhibitors 1 open · Serotonin receptor agonists 1 open · Factor Xa inhibitors 1 open · Antimuscarinics 13

Coming up

223studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 376 Spinal Cord Injuries studies recruiting now, 167 (44%) set no upper age limit and 158 (42%) stop at 75 or younger. 41 (11%) take children under 18. 2 (1%) are for women only and 6 (2%) for men only; 52 (14%) take healthy volunteers.

Recruiting studies that take each age, of 376
AgeWomenMen
1019 (5%)19 (5%)
18310 (82%)314 (84%)
30362 (96%)366 (97%)
40362 (96%)366 (97%)
50361 (96%)364 (97%)
65339 (90%)341 (91%)
75252 (67%)255 (68%)
85182 (48%)184 (49%)

Across all 2,028 studies, recruiting or not: 49% stop at 75 or younger and 29% at 65; 12% take children; 1% are for women only and 3% for men only; 18% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Spinal Cord Injuries studies take

Of 51 phase 1 interventional studies under Spinal Cord Injuries, half reached primary completion within 36 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 136 mo24–55 · 51 studies—38 mo25–55 · 40 studies
Phase 1/230 mo24–60 · 24 studies——
Phase 246 mo28–64 · 49 studies—46 mo28–64 · 44 studies
Phase 442 mo26–63 · 19 studies——
Interventional, no phase36 mo17–64 · 839 studies15 mo6–28 · 49 studies37 mo18–65 · 790 studies
Observational39 mo16–82 · 135 studies—36 mo16–74 · 124 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered22

Show 17 more

Studies

Recruiting first, then most recently updated. Showing 50 of 2,028. Browse all 2,028 → or search them.